We are Sorry, This Page doesn't Exist

The company already is in a bitter proxy fight with a hedge fund that claims its board has provided weak oversight of management as it allegedly ignores a side effect of its gene therapy against a blinding eye disease......»»

The company has raised about $265 million, including $148 million in a Series C round disclosed last month......»»

The company, with sites in the Bay Area, Philadelphia and London, also counts Genentech and a handful of other local biotechs as its competition......»»

Uniqure NV (NASDAQ: QURE) has read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

The company has eight full-time employees and plans to add up to six staff members this year as a result of the financing......»»

Just south of Houston and the Texas Medical Center, Pearland is home to one of the region’s most noteworthy life science companies, Lonza. A Switzerland-based company, Lonza’s Pearland facility is one of the largest cell and gene therapy man.....»»

Shares of bluebird bio Inc (NASDAQ: BLUE) were sinking Tuesday morning following an adverse clinical pipeline development. read more.....»»

Shares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimental Huntington's disease treatment. The boar.....»»

In the wake of its potential $4 billion deal with Bayer, the firm is expanding its leadership team......»»

Aronora has secured $25 million in grants but is seeking a partner to take its drug candidates into Phase 3 clinical trials......»»

The Gaithersburg company is partnering with New York's Mount Sinai Health System to test the therapy......»»

The biotech company says it will look long term at bringing manufacturing in-house again, but it plans to sublease the 153,000-square-foot site it had planned to open next year......»»

Shares of the micro-cap gene therapy company Genprex Inc (NASDAQ: GNPX) were advancing strongly on above-average volume Tuesday. read more.....»»

BioNTech SE (NASDAQ: BNTX) shares are trading higher on Thursday, after the company said it would partner with Pfizer (NYSE: PFE) to initiate first clinical trials of the coronavirus vaccine as early as this month. read more.....»»

Shares of Novavax Inc. jumped 9% in premarket trading on Wednesday after the company said it had identified a COVID-19 vaccine candidate. There are no approved vaccines for the novel coronavirus. Novavax said it plans to begin Phase 1 clinical trials in .....»»

The second phase of the clinical trials of the novel coronavirus (COVID-19) vaccine of Moderna Inc. (NASDAQ: MRNA) could begin in spring, the biotechnology company's chairman Noubar Afeyan read more.....»»

InflaRx shares jumped early on Wednesday after the company announced that it has enrolled its first patient into a clinical trial for the treatment of severe COVID-19-induced pneumonia......»»

The Houston company's drug candidate has shown promising results in combatting MERS and SARS in mice in pre-clinical trials......»»

NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene.....»»